FI3971177T3 - Aminopyridiinijohdannaisia ja niiden käyttö selektiivisinä alk-2:n estäjinä - Google Patents

Aminopyridiinijohdannaisia ja niiden käyttö selektiivisinä alk-2:n estäjinä Download PDF

Info

Publication number
FI3971177T3
FI3971177T3 FIEP21202619.9T FI21202619T FI3971177T3 FI 3971177 T3 FI3971177 T3 FI 3971177T3 FI 21202619 T FI21202619 T FI 21202619T FI 3971177 T3 FI3971177 T3 FI 3971177T3
Authority
FI
Finland
Prior art keywords
nicotinamide
amino
phenyl
azabicyclo
hexan
Prior art date
Application number
FIEP21202619.9T
Other languages
English (en)
Finnish (fi)
Inventor
Jialiang Li
Luca Arista
Sreehari Babu
Jianwei Bian
Kai Cui
Michael Patrick Dillon
Rene Lattmann
Lv Liao
Rita Ramos
Nikolaus Johannes Stiefl
Thomas Ullrich
Peggy Usselmann
Xiaoyang Wang
Liladhar Murlidhar Waykole
Sven Weiler
Yubo Zhang
Yizong Zhou
Tingying Zhu
Dimitrios Lizos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3971177T3 publication Critical patent/FI3971177T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
FIEP21202619.9T 2016-07-20 2017-07-18 Aminopyridiinijohdannaisia ja niiden käyttö selektiivisinä alk-2:n estäjinä FI3971177T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20

Publications (1)

Publication Number Publication Date
FI3971177T3 true FI3971177T3 (fi) 2024-07-30

Family

ID=60991950

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21202619.9T FI3971177T3 (fi) 2016-07-20 2017-07-18 Aminopyridiinijohdannaisia ja niiden käyttö selektiivisinä alk-2:n estäjinä

Country Status (25)

Country Link
US (4) US10710980B2 (https=)
EP (3) EP3971177B1 (https=)
JP (4) JP7030776B2 (https=)
KR (7) KR20240155367A (https=)
CN (2) CN109641871B (https=)
AR (1) AR109108A1 (https=)
AU (5) AU2017298187B2 (https=)
CY (1) CY1124967T1 (https=)
DK (2) DK3487851T3 (https=)
EA (2) EA202190285A1 (https=)
ES (2) ES2984746T3 (https=)
FI (1) FI3971177T3 (https=)
HR (2) HRP20211868T1 (https=)
HU (2) HUE057328T2 (https=)
LT (2) LT3971177T (https=)
MX (2) MX388518B (https=)
PL (2) PL3971177T3 (https=)
PT (2) PT3971177T (https=)
RS (2) RS62819B1 (https=)
RU (1) RU2747318C2 (https=)
SI (2) SI3971177T1 (https=)
SM (2) SMT202100723T1 (https=)
TW (5) TW202509017A (https=)
UY (1) UY37331A (https=)
WO (1) WO2018014829A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388518B (es) * 2016-07-20 2025-03-19 Novartis Ag Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
JP7717065B2 (ja) * 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
WO2021257532A1 (en) * 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
KR102913358B1 (ko) * 2020-10-29 2026-01-14 주식회사 엘지화학 중수소화 화합물의 분석방법, 소자 제조용 중수소화 화합물의 선별방법 및 전자 소자의 제조방법
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
CA2149441C (en) 1992-11-17 2004-03-02 Kohei Miyazono Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
AU2005247699A1 (en) 2004-05-27 2005-12-08 Pfizer Inc. Aminopyridine derivatives as selective dopamine D3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
BRPI0607913A2 (pt) 2005-04-08 2010-03-23 Eisai R&D Man Co Ltd agente terapÊutico para discinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071241A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
CA2649770C (en) 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
EP2062048A4 (en) 2006-09-12 2009-12-02 Gen Hospital Corp METHOD FOR IDENTIFYING CELL SIGNALING MODULATING COMPOUNDS AND METHOD FOR USING SUCH COMPOSITES
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
CN105198981B (zh) 2010-08-20 2019-07-16 惠氏有限责任公司 经设计的成骨蛋白
US20130310374A1 (en) 2010-12-06 2013-11-21 Piramal Enterprises Limited` Substituted Imidazoquinoline Derivatives
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
CN108484449A (zh) 2011-09-09 2018-09-04 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
MX394360B (es) * 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
PE20181017A1 (es) 2015-08-31 2018-06-26 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como farmacos terapeuticos
US11462835B2 (en) 2016-07-20 2022-10-04 Qorvo Us, Inc. Method for tuning an antenna with a DVC
MX388518B (es) 2016-07-20 2025-03-19 Novartis Ag Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
EP3487851B1 (en) 2021-10-20
TW202509017A (zh) 2025-03-01
HUE057328T2 (hu) 2022-05-28
AU2021201424A1 (en) 2021-03-25
AU2021201424B2 (en) 2022-10-20
AU2019246857B2 (en) 2020-12-24
KR102359707B1 (ko) 2022-02-09
HRP20211868T1 (hr) 2022-03-04
KR20230117248A (ko) 2023-08-07
US10947218B2 (en) 2021-03-16
TWI851226B (zh) 2024-08-01
JP2023089012A (ja) 2023-06-27
KR20220021023A (ko) 2022-02-21
MX2019000837A (es) 2019-07-04
RS62819B1 (sr) 2022-02-28
CN114014844B (zh) 2024-10-01
AU2017298187A1 (en) 2018-12-20
EP3971177A1 (en) 2022-03-23
MX388518B (es) 2025-03-19
CN109641871A (zh) 2019-04-16
EP4442317A3 (en) 2025-01-01
SI3971177T1 (sl) 2024-10-30
PT3971177T (pt) 2024-07-30
US20190161474A1 (en) 2019-05-30
KR102281550B1 (ko) 2021-07-27
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
PT3487851T (pt) 2022-01-07
LT3971177T (lt) 2024-08-26
KR20210094138A (ko) 2021-07-28
RU2021111037A (ru) 2021-05-13
WO2018014829A1 (en) 2018-01-25
HRP20241015T1 (hr) 2024-11-08
EA202190285A1 (ru) 2021-08-31
EP4442317A2 (en) 2024-10-09
EP3487851A4 (en) 2019-12-25
CY1124967T1 (el) 2023-01-05
BR112019000941A2 (pt) 2019-04-30
TWI806385B (zh) 2023-06-21
DK3971177T3 (da) 2024-07-15
TW201805277A (zh) 2018-02-16
MX2021014852A (es) 2022-01-18
RU2019104609A (ru) 2020-08-20
AR109108A1 (es) 2018-10-31
DK3487851T3 (da) 2021-12-20
KR20240155367A (ko) 2024-10-28
KR102454129B1 (ko) 2022-10-14
TW202134228A (zh) 2021-09-16
EA037520B1 (ru) 2021-04-07
AU2019246857A1 (en) 2019-10-31
TW202220969A (zh) 2022-06-01
US20200299265A1 (en) 2020-09-24
CN114014844A (zh) 2022-02-08
EP3487851A1 (en) 2019-05-29
AU2024205058A1 (en) 2024-08-15
JP7834830B2 (ja) 2026-03-24
US20260116869A1 (en) 2026-04-30
JP7253086B2 (ja) 2023-04-05
EP3971177B1 (en) 2024-06-26
ES2902521T3 (es) 2022-03-28
SMT202400335T1 (it) 2024-09-16
AU2023200265B2 (en) 2024-08-15
CN109641871B (zh) 2021-10-22
KR20240074904A (ko) 2024-05-28
JP2022078137A (ja) 2022-05-24
KR102559539B1 (ko) 2023-07-26
JP7030776B2 (ja) 2022-03-07
JP7584553B2 (ja) 2024-11-15
JP2019521167A (ja) 2019-07-25
US10710980B2 (en) 2020-07-14
TW202336011A (zh) 2023-09-16
JP2025032086A (ja) 2025-03-11
LT3487851T (lt) 2021-12-27
KR20220143770A (ko) 2022-10-25
RU2019104609A3 (https=) 2020-09-30
US20210155606A1 (en) 2021-05-27
KR102667331B1 (ko) 2024-05-21
RU2021111037A3 (https=) 2022-02-10
EA201990343A1 (ru) 2019-06-28
RU2747318C2 (ru) 2021-05-04
KR102719881B1 (ko) 2024-10-23
TWI712598B (zh) 2020-12-11
US12466808B2 (en) 2025-11-11
PL3487851T3 (pl) 2022-04-11
RS66041B1 (sr) 2024-11-29
AU2023200265A1 (en) 2023-02-16
CA3030332A1 (en) 2018-01-25
PL3971177T3 (pl) 2024-10-28
UY37331A (es) 2018-02-28
TWI755255B (zh) 2022-02-11
KR20190026917A (ko) 2019-03-13
ES2984746T3 (es) 2024-10-30
HUE067992T2 (hu) 2024-12-28
SI3487851T1 (sl) 2022-03-31
SMT202100723T1 (it) 2022-01-10

Similar Documents

Publication Publication Date Title
FI3971177T3 (fi) Aminopyridiinijohdannaisia ja niiden käyttö selektiivisinä alk-2:n estäjinä
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
JP2019521167A5 (https=)
JP2010508338A5 (https=)
RU2012126987A (ru) Спироиндолциклопропаниндолиноны в качестве модуляторов амрк
JP2015524798A5 (https=)
WO2016197009A1 (en) Triazoles for the treatment of demyelinating diseases
TWI669300B (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
RU2010108282A (ru) Соединения хинолина, пригодные для лечения нарушений, являющихся ответом на модуляцию рецептора 5-нт6 серотонина
CA2844830A1 (en) Novel imidazole amines as modulators of kinase activity
JP2018515489A5 (https=)
JP2018505145A5 (https=)
CA3106470A1 (en) T-type calcium channel blocker
WO2022111700A1 (zh) 哒嗪酮衍生物及其在医药上的应用
RU2013120338A (ru) Производное 1,2,4-триазолана
AU2018237987A1 (en) Isoxazole carboxamide compounds and uses thereof
WO2022224166A1 (en) Compounds as lxr agonists
RU2690679C2 (ru) Новые пиримидинимидазоламины в качестве модуляторов активности киназы
EP3950059A1 (en) Use of t-type calcium channel blocker for treating pruritus
CN114901640A (zh) 适用于治疗血脂异常的新型化合物
RU2024125208A (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
CA3113573A1 (en) Isoxazole carboxamide compounds and uses thereof
RU2008105807A (ru) Производные замещенного-3-сульфонилиндазола в качестве 6-лиганд 5-гидрокситриптамина
EP4211118A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
WO2022063646A1 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors